Well-being in Major Depression and Social Phobia with and without Comorbidity by Wersebe, Hanna et al.
International Journal of Clinical and Health Psychology (2018) 18, 201--208
www.elsevier.es/ijchp
International Journal
of Clinical and Health Psychology
ORIGINAL ARTICLE
Well-being in major depression and social phobia with
and without comorbidity
Hanna Wersebea, Roselind Lieba, Andrea H. Meyera, Marcel Michea,
Thorsten Mikoteitb,e, Christian Imbodenb,c, Jürgen Hoyerd, Klaus Badere,
Martin Hatzingerb, Andrew T. Glostera,f,∗
a Department of Psychology, Division of Clinical Psychology and Epidemiology, University of Basel, Switzerland
b Psychiatric Services Solothurn and University of Basel, Switzerland
c Private Clinic Wyss, Muenchenbuchsee, Switzerland
d Technische Universität Dresden, Clinical Psychology and Psychotherapy, Germany
e Psychiatric Hospital, University of Basel, Basel, Switzerland
f Department of Psychology, Division of Clinical Psychology and Intervention Science, University of Basel, Switzerland
Received 27 February 2018; accepted 29 June 2018
Available online 6 August 2018
KEYWORDS
Mental health;
Major Depressive
Disorder;
Social Phobia;
Comorbidity;
Well-being;
Descriptive study
Abstract Background/Objective: Lower levels in well-being have been observed in individuals
with Major Depression (MDD) and Social Phobia (SP), but well-planned direct comparisons with
control individuals, not suffering from a mental disorder, are lacking. Furthermore, MDD is
highly comorbid with anxiety disorders, and SP with depressive disorders. This study is among
the ﬁrst to examine differences in well-being in individuals with a clinical diagnosis of MDD or SP
compared to individuals with no such diagnosis and to test differences in well-being within the
combined diagnostic categories respective with and without anxiety-depressive comorbidity.
Method: Participants were 119 individuals with a diagnosis of MDD, 47 SP and 118 controls.
Results: Results revealed that overall well-being as well as emotional, psychological, and social
well-being were lower in the MDD and SP group compared to the control group. Individuals
with comorbidity reported lower well-being than individuals without comorbidity. Conclusions:
These ﬁndings have clinical implications as presence of comorbidity may require a different
therapeutic approach than with no comorbidity.
© 2018 Asociacio´n Espan˜ola de Psicolog´ıa Conductual. Published by Elsevier Espan˜a, S.L.U. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
∗ Corresponding author: University of Basel, Department of Psychology, Division of Clinical Psychology and Intervention Science, Mission-
sstrasse 60-62, CH-4055 Basel, Switzerland.
E-mail address: andrew.gloster@unibas.ch (A.T. Gloster).
https://doi.org/10.1016/j.ijchp.2018.06.004
1697-2600/© 2018 Asociacio´n Espan˜ola de Psicolog´ıa Conductual. Published by Elsevier Espan˜a, S.L.U. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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PALABRAS CLAVE
Salud mental;
depresión;
fobia social;
comorbilidad;
bienestar;
estudio descriptivo
Bienestar en depresión grave y fobia social con y sin comorbilidad
Resumen Antecedentes/Objetivo: Se han observado niveles bajos de bienestar en individuos
con depresión grave (DG) y fobia social (FS). Sin embargo, las comparaciones directas planiﬁ-
cadas con individuos controles que no padecen ningún trastorno mental son escasas. Además,
la DG se suele presentar con trastornos de ansiedad, y la FS con trastornos depresivos. Este
estudio es uno de los primeros en examinar las diferencias entre el bienestar en individuos
con un diagnóstico clínico de DG o FS, comparados con individuos sin dicho diagnóstico y en
comprobar las diferencias de bienestar dentro de cada categoría de diagnóstico en realación
a individuos con y sin comorbilidad. Método: Participaron 119 individuos con un diagnóstico
de DG, con base en la SCID, 47 con FS y 118 controles. Resultados: Los resultados revelaron
que el bienestar general, así como el bienestar emocional, psicológico y social eran inferiores
en el grupo de DG y FS en comparación con el grupo control. Los individuos con comorbili-
dad informaron un menor bienestar que los individuos sin comorbilidad. Conclusiones: Estos
resultados tienen repercusión clínica, pues la presencia de la comorbilidad puede requerir un
acercamiento terapéutico diferente al de un único trastorno.
© 2018 Asociacio´n Espan˜ola de Psicolog´ıa Conductual. Publicado por Elsevier Espan˜a, S.L.U.
Este es un art´ıculo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Major depressive disorders (MDD) and Social Phobia (SP)
are among the most frequent mental disorders (Kessler,
Chiu, Demler, & Walters, 2005) affecting a substantial num-
ber of individuals every year and with ranges between
17.2-19 million for MDD and 5.4-9.3 million for SP in Europe
(Wittchen et al., 2011). Both MDD and SP are associated with
high drop out rates in the labor market and economic costs
( Banerjee, Chatterji, & Lahiri, 2014; Chiu, Lebenbaum,
Cheng, Oliveira, & Kurdyak, 2017; Jia & Lubetkin, 2017;
Wittchen et al., 2011). Further, MDD and SP are related to
a high burden by impairments in social role performance,
and disturbed relationships (Richards et al., 2016; Wittchen,
Nelson, & Lachner, 1998).
Comorbidity between mood and anxiety disorders is com-
mon (Beesdo et al., 2007; Jacobi et al., 2004; Kessler et al.,
2005). Among individuals with MDD, 57.5% also meet criteria
for at least one other 12-month anxiety disorder (Kessler,
Merikangas, & Wang, 2007). Similarly, among individuals
with SP 14.9% meet lifetime criteria for MDD (Kessler, Stang,
Wittchen, Stein, & Walters, 1999) and 60% of individuals in
treatment for SP meet criteria for depression (Merikangas &
Angst, 1995). The combination of high prevalence, comor-
bidity and impairment make MDD and SP important disorders
from a public health perspective. Research has shown that
individual and economic difﬁculties are even more pro-
nounced in individuals with comorbid depression and anxiety
disorders (Beesdo et al., 2007; Cavicchioli et al., 2018;
Kessler et al., 2003). Furthermore, the presence of comor-
bidity is associated with higher severity, mortality and longer
duration of symptoms (Abreu et al., 2018; Kessler et al.,
2005; Meier et al., 2016), and higher risk for treatment
resistance (Rizvi et al., 2014).
Given the high impact of depressive and anxiety disor-
ders on everyday life, many individuals seek professional
help (Boerema et al., 2016; Johansson, Carlbring, Heedman,
Paxling, & Andersson, 2013; Magaard, Seeralan, Schulz, &
Brütt, 2017). However, efforts to treat MDD and SP tend to
aim to reduce speciﬁc symptoms (Lorenzo-Luaces, Keefe,
& DeRubeis, 2016), thereby assuming that well-being will
increase as well. Interestingly, there is accumulating evi-
dence showing that the absence of mental disorders or
symptoms are only moderately related to the presence of
well-being (Lamers, Westerhof, Glas, & Bohlmeijer, 2015;
Trompetter, Lamers, Westerhof, Fledderus, & Bohlmeijer,
2017). This relation has been formulated in a two-continua
model that states that although they are related, ‘‘mental
health and mental illness are not opposite ends of a single
continuum’’ (Keyes, 2005, p. 546). According to that model
(Keyes, 2005), well-being includes emotional well-being,
psychological well-being and social well-being. Emotional
well-being refers to feelings of pleasure and happiness
including life satisfaction. Psychological well-being refers
to feelings of self-acceptance, environmental mastery and
positive relations to others. Social Well-Being refers to feel-
ings of social contribution, integration and acceptance. The
model implies that an individual experiencing many symp-
toms of psychopathology is more likely to experiencing
low well-being. However, this association is only moderate.
Thus, an individual may be suffering from mental illness and
still experience well-being at the same time (Keyes, 2005).
To date, there is no research yet that examined the implica-
tions of the two-continua model in terms of differences in
well-being in adults with and without MDD and SP.
In the light of the high depression-anxiety comorbidity
and its clinical implications, it is important to understand
whether comorbidity renders further reduction in well-
being. The gained knowledge may help to improve current
interventions. Perhaps, in clinical practice well-being should
be addressed more in individuals with comorbidity. As for the
depression-anxiety comorbidity, research to date is mainly
on quality of life (Rapaport, Clary, Fayyad, & Endicott, 2005;
Zhou et al., 2017) and there is little research comparing
quality of life in individuals with depression-anxiety comor-
bidity to individuals with no comorbidity (Johansson et al.,
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2013; Norberg, Diefenbach, & Tolin, 2008). These studies
consistently showed lower quality of life in individuals with
depression-anxiety comorbidity when compared to individ-
uals without comorbidity. For instance, individuals with
anxiety-depressive comorbidity had lower health related
quality of life than those with no comorbidity (Riihimäki
et al., 2016). Another study showed that anxiety-depressive
comorbidity was associated with lower overall quality of life
compared to the comparative community sample (Rapaport
et al., 2005). To date, no study has examined comorbidity
in respect to well-being in individuals with MDD and SP.
This study aimed to address this gap in research while
building on the relevance of well-being (Keyes, 2002) and
examines differences in well-being in individuals with a pri-
mary MDD or SP diagnosis compared to controls as well as
in individuals with a comorbid anxiety or depressive disor-
ders. We hypothesized that (1a) individuals with MDD report
lower well-being than controls, (1b) Individuals with SP
report lower well-being than controls, and that (2) Indi-
viduals with comorbidity within the combined diagnostic
categories report lower well-being than individuals without
comorbidity.
Method
Participants
Participants were recruited from March 2014 to August 2016
through leaﬂets, Internet advertisements, and through three
(university) clinics in Germany and Switzerland (Gloster,
Miché et al., 2017) as well as private practices in Switzer-
land. Participants consisted of n = 118 with primary DSM-IV
MDD, n = 47 with primary DSM-IV SP, and n = 119 with neither
MDD nor SP (controls). For the purpose of comparisons across
participant groups, the clinical groups were subdivided on
the basis of presence of current comorbidity: MDD (n = 74
with comorbid anxiety disorders; n = 44 without comorbid
anxiety disorder) and SP (n = 9 with comorbid depressive
disorders and n = 38 without comorbid depressive disorder).
Comorbid anxiety disorders included Social Phobia, Speciﬁc
Phobias, and Panic disorder with or without agoraphobia,
and Generalized Anxiety Disorder. Comorbid depressive dis-
orders included MDD and Dysthymic Disorder. Individuals in
the MDD group could present multiple anxiety comorbidi-
ties, and individuals in the SP group could present multiple
depressive comorbidities. Current primary diagnoses (i.e.
last four weeks) were determined with the Structured Clin-
ical Interview for DSM- IV Axis I Disorders (SCID; Wittchen,
Wunderlich, Gruschwitz, & Zaudig, 1997). All comorbid diag-
noses refer to the past month (e.g. Social Phobia, Speciﬁc
Phobias, and Panic disorder with or without agoraphobia),
except for Generalized Anxiety Disorder that refers to the
last six months and Dysthymic Disorder that refers to the last
two years. Demographic information can be seen in Table 1.
Procedure
This study used a subset of a quasi-experimental, inten-
sive, longitudinal study with diagnostic status of group as
the quasi-experimental factor examining symptom ﬂuctu-
ations and memories thereof by means of event sampling
Table 1 Demographic information of sample and sample
characteristics.
MDD n = 118 SP n = 47 Controls
n = 119
Age in years
Mean (SD) 32.7 (12.0) 28.3 (7.8) 32.2 (12.0)
Median 29.0 26.0 28.0
Sex
Male 33.9 34.0 32.8
Female 66.1 66.0 67.2
Years of education
8-10 21.1 9.3 12.0
11-13 51.4 67.4 53.0
14+ 27.5 23.3 35.0
Employment status
Employed 52.5 38.3 57.1
Unemployed 46.6 61.7 39.5
methodology (for details see Gloster, Klotsche et al., 2017).
Trained psychology graduate and doctoral students collected
the data. For the present study, data from the baseline
assessment of participants in the MDD, SP and control group
were used. The study team rated diagnoses on the Clini-
cal Rating Scale (adapted: Unnewehr, Schneider, & Margraf,
1995), in which the highest rating corresponded to the pri-
mary diagnosis. Participants across the three groups were
matched by age and sex. Further inclusion criteria were age
between 18-65 years and the ability to understand German.
Exclusion criteria were active current suicidal intent and
substance dependence. All procedures were approved by the
local ethics committee.
Measures
Structured Clinical Interview for DSM- IV Axis I Disorders
(SCID; Wittchen et al., 1997). Diagnoses of mental disor-
ders were assessed with the Structured Clinical Interview
for DSM- IV Axis I Disorders (SCID; Wittchen et al., 1997).
The SCID is a semistructured interview for clinicians and
trained researchers for making DSM- IV Axis I diagnoses. The
interview is separated into different sections correspond-
ing categories of diagnoses. Sections begin with an entry
question that allow the interviewer to skip the associated
questions if the entry conditions are not met. Symptoms
are coded as present, or absent. Studies on the psychomet-
ric properties of the SCID indicated good reliabilities (Skre,
Onstad, Torgersen, & Kringlen, 1991; Williams et al., 1992).
Inter-rater agreement has been reported to be between .72
was SP and .93 for MDD (Skre et al., 1991).
Mental Health Continuum-Short Form (MHC-SF; Keyes,
2005)
The MHC-SF (Keyes, 2005) is a 14-item questionnaire
that measures well-being on a scale from 1 (never) to 6
(every day), whereas the emotional well-being (3 items),
social well-being (5 items) and psychological well-being (6
items) in the last month was captured. For each aspect
of well-being a mean score across the respective items
was calculated. Higher scores indicate greater emotional,
social and psychological well-being (Keyes, 2005; Lamers,
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Westerhof, Bohlmeijer, Klooster, & Keyes, 2011). The MHC-
SF has presented good psychometric properties across
various age groups and countries (Cronbach’s  = .74-.89;
Lamers, Westerhof, Bohlmeijer, Klooster, & Keyes, 2011;
Westerhof & Keyes, 2010).
Statistical analysis
Data were analyzed using Statistical Package for the Social
Sciences (SPSS) version 22.0. Prior to analysis data was
tested for normality and outliers. Our hypotheses that
individuals with a diagnosis report lower well-being than
controls (hypothesis 1a and 1b), and that individuals with
comorbidity within the combined diagnostic categories
report lower well-being than individuals without comorbid-
ity (hypothesis 2) were tested by means of a general linear
model with orthogonal contrasts. The two a priori deﬁned
contrasts were a) control group versus MDD or SP groups, and
b) comorbidity versus no comorbidity within the combined
MDD and SP groups. We controlled for the recruitment loca-
tion. The  level for statistical signiﬁcance for all analyses
was set to .05. Between-group effect sizes were calculated
according to Cohen’s d. Effect sizes of 0.2, 0.5, and 0.8 refer
to small, moderate, and large effects, respectively (Cohen,
1988).
Results
Descriptive statistics
Descriptive statistics of all measures involved in the analyses
are shown on the left-hand side of Table 2.
Individuals with a MDD report lower
well-being than controls (Hypothesis 1a)
Overall well-being as well as emotional, social and psycho-
logical well-being were all signiﬁcantly lower in individuals
with MDD compared to the control participants, with large
effect sizes throughout (Table 2).
Individuals with a SP report lower well-being
than controls (Hypothesis 1b)
Likewise, individuals with SP endorsed in signiﬁcantly lower
overall well-being, emotional, social and psychological well-
being compared to the control group, with large effect sizes,
respectively (Table 2).
Individuals with comorbidity within the
combined diagnostic categories report lower
well-being than individuals without
comorbidity (Hypothesis 2)
Signiﬁcant differences were found among individuals with
and without comorbidity within the combined diagnostic
categories (i.e. MDD and SP) in overall, as well as emo-
tional, social and psychological well-being (Table 3). Thus,
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Table 3 Descriptive measures of clinical groups with and without anxiety-depressive comorbidity and results of group
comparison.
Combined MDD and SP comorbidity vs. no comorbidity
p-value 95% CI Mean difference
Measure
Well-Being <.001 -0.80, -0.25 -0.49
Emotional <.001 -1.04, -0.44 -0.71
Social .001 -0.85. -0.22 -0.49
Psychological .009 -0.73, -0.10 -0.38
Note. CI = Conﬁdence Interval; MDD=Major Depressive Disorder; SP = Social Phobia. Mean differences refer to the difference between
the respective clinical group and the control group.
individuals with comorbidity reported lower overall, as well
as emotional, social and psychological well-being.
Discussion
The aim of this study was to investigate differences in well-
being in individuals with a diagnosis of MDD or SP and in
individuals with comorbidity within the combined diagnos-
tic groups, respectively. To the best of our knowledge, this
is the ﬁrst study to examine differences in individuals with
MDD or SP in well-being with an explicit control group. As
hypothesized, we found that individuals with a diagnosis
showed lower well-being compared to controls. This ﬁnding
supports previous literature reporting low to medium ranges
in quality of life in individuals with MDD and SP (Rapaport
et al., 2005). A previous study compared well-being to a
community norm (Rapaport et al., 2005), however, we are
unaware of any studies that tested these patterns of well-
being against an control group matched for age and sex.
While previous studies used quality of life as outcome mea-
sures to examine differences in individuals with a clinical
diagnosis compared to those without a clinical diagnosis
(Johansson et al., 2013; Norberg et al., 2008), we used an
explicit measure of well-being. In contrast to quality-of-life
measures, the well-being measure applied in the present
study incorporates the presence of emotional, social and
psychological well-being and thus is taking different aspects
of well-being into account. Importantly, this concept of well-
being can be directly linked to the deﬁnition of well-being
of the World Health Organization, WHO (2004), which states
that well-being is present when ‘‘the individual realizes his
or her own abilities, can cope with the normal stresses
of life, can work productively and fruitfully, and is able
to make a contribution to his or her community’’ (World
Health Organization, WHO, 2004). Furthermore, it is known
that individuals with MDD and SP experience lower positive
affect, emotions and evaluate events as less pleasant and
more stressful compared to individuals without MDD and
SP (Blanco & Joormann, 2018; Dunkley et al., 2017), fac-
tors that likely contribute to a generally lower well-being
in individuals with MDD and SP. The association of well-
being and depression is further interlinked with age in that
younger adults experience higher symptoms of depression
(Schönfeld, Brailovskaia, & Margraf, 2017). Moreover, indi-
viduals with MDD and SP are clearly limited in daily activities
(e.g. missed work days, throwbacks at work) in comparison
to individuals without MDD and SP (e.g. Broadhead, Blazer,
George, & Tse, 1990).
As hypothesized, individuals with comorbidity reported
lower well-being than individuals with no anxiety-depressive
comorbidity. Although there is research in the ﬁeld of quality
of life, a construct that is sharing similarities with well-
being, there is no research so far in terms of differences
in well-being in adults with and without anxiety-depressive
comorbidities. Our ﬁndings are consistent with those stud-
ies reporting lower quality of life (Cavicchioli et al., 2018;
Norberg et al., 2008; Zhou et al., 2017) in individuals with
comorbid disorders, perhaps due to the higher symptom
burden, compared to individuals no comorbidity. For ins-
tance, a study examining associations of anxiety-depression
comorbidity and quality of life found that comorbidity to
depression in anxiety disorders is linked to lower quality of
life (Norberg et al., 2008). We extended their ﬁndings by
including a depression diagnosis group, showing that depres-
sion was associated with low well-being ratings already.
Likewise, a study investigating comorbidity in anxiety dis-
orders indicated that well-being decreased as individuals
moved from having one disorder to having multiple disor-
ders (Sherbourne et al., 2010). This indicates that clinicians
should be aware for patients presenting depression-anxiety
comorbidity and that there is greater burden on those
with comorbidity. The presence of comorbidity may require
a different therapeutic approach than with single dis-
orders. Indeed, there is evidence that acceptance- and
mindfulness-based interventions are linked to improved
outcomes for patients with comorbidity, and traditional
Cognitive-Behavioral Therapy (CBT) more helpful for single
disorders (Arch & Ayers, 2013). This is in line with previous
research, e.g. a switching trial from CBT to Acceptance and
Commitment Therapy (ACT) in treatment-resistant patients,
that presented a high comorbidity rate (Gloster et al., 2015;
Gloster, Klotsche et al., 2017).
Furthermore, we observed a descriptive pattern in well-
being in that individuals in the control group reported the
highest well-being, followed by individuals with SP with-
out comorbidity and ultimately individuals with MDD without
comorbidity. This pattern corresponds to one found in earlier
studies (Rapaport et al., 2005; Riihimäki et al., 2016), which
found that impairments in quality of life were higher in indi-
viduals with MDD than in individuals with SP. This suggests
that SP may have a rather speciﬁc impact on well-being in
individuals’ lives, while MDD may have a more general and
overarching impact on peoples’ lives.
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This study needs to be interpreted in the light of several
limitations. First, we relied on self-reported measurements
to assess well-being. These are prone to biases inherent in
this assessment approach. Additional analyses of informa-
tion stemming from other sources (e.g., friends and family
or employers) may have resulted in different overall ﬁnd-
ings as self-report measures may not capture well-being in
their full complexity. Second, the study sample is limited to
participants with and without MDD and SP. This and because
of the potential effects of self-selection and treatment, the
results may raise the question of generalizability. Third, we
had no data on the long-term and chronic course of the two
clinical disorders. Thus ﬁndings cannot be generalized to
individuals with chronic depression and their association to
well-being.
With these limitations in mind, the current study
extended the existing body of literature by explicitly inves-
tigating differences in well-being in individuals with and
without MDD or SP, as well as in the subgroups of MDD or
SP with and without comorbidity to anxiety disorders or
to depressive disorders. Also, this is the ﬁrst study exam-
ining the implications of the 2-continua model in terms
of well-being in adults with and without MDD and SP.
Future studies should, for instance, investigate the role
of well-being in different samples other than depressive
or anxiety disorders to determine whether results are not
limited to these particular clinical groups. It may also
be helpful to incorporate well-being measures in addition
to treatment outcome assessments to evaluate treatment
outcomes in an additional informative way and to aug-
ment symptom-based treatment change analyses. Moreover,
studies should clarify the temporal relationship of a clin-
ical diagnosis of MDD or SP and low well-being. This is
important as well-being are both diminished in individuals
with a clinical diagnosis and evaluating (temporal) path-
ways may allow to intervene with targeted psychological
help.
Our ﬁndings not only suggest that individuals with a
clinical diagnosis (i.e. MDD or SP) clearly differed from
individuals with no clinical diagnosis of MDD or SAD (i.e.
controls) in respect to well-being, but also that individuals
with comorbidity within both diagnostic categories engage
in lower well-being than those without comorbidity. Thus,
our ﬁndings are of clinical importance and may indicate
the need to enhance well-being (Keyes, 2007) in individu-
als with a clinical diagnosis. One intervention that promotes
well-being is ACT (Ciarrochi & Kashdan, 2013).
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